The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2)

Winger, Jonathan A.; Hantschel, Oliver; Superti-Furga, Giulio; Kuriyan, John
January 2009
BMC Structural Biology;2009, Vol. 9, Special section p1
Academic Journal
Background: Imatinib represents the first in a class of drugs targeted against chronic myelogenous leukemia to enter the clinic, showing excellent efficacy and specificity for Abl, Kit, and PDGFR kinases. Recent screens carried out to find off-target proteins that bind to imatinib identified the oxidoreductase NQO2, a flavoprotein that is phosphorylated in a chronic myelogenous leukemia cell line. Results: We examined the inhibition of NQO2 activity by the Abl kinase inhibitors imatinib, nilotinib, and dasatinib, and obtained IC50 values of 80 nM, 380 nM, and >100 µM, respectively. Using electronic absorption spectroscopy, we show that imatinib binding results in a perturbation of the protein environment around the flavin prosthetic group in NQO2. We have determined the crystal structure of the complex of imatinib with human NQO2 at 1.75 Å resolution, which reveals that imatinib binds in the enzyme active site, adjacent to the flavin isoalloxazine ring. We find that phosphorylation of NQO2 has little effect on enzyme activity and is therefore likely to regulate other aspects of NQO2 function. Conclusion: The structure of the imatinib-NQO2 complex demonstrates that imatinib inhibits NQO2 activity by competing with substrate for the active site. The overall conformation of imatinib when bound to NQO2 resembles the folded conformation observed in some kinase complexes. Interactions made by imatinib with residues at the rim of the active site provide an explanation for the binding selectivity of NQO2 for imatinib, nilotinib, and dasatinib. These interactions also provide a rationale for the lack of inhibition of the related oxidoreductase NQO1 by these compounds. Taken together, these studies provide insight into the mechanism of NQO2 inhibition by imatinib, with potential implications for drug design and treatment of chronic myelogenous leukemia in patients.


Related Articles

  • Antineoplastics/prednisolone.  // Reactions Weekly;4/29/2006, Issue 1099, p6 

    Reports on the development of chronic eosinophilic leukemia in a 43-year-old man after receiving antineoplastics and rednisolone for non-Hodgkin's lymphoma. Combination chemotherapy courses received by the patient for about 11 years; Development of leucocytosis with 73% eosinophils in the...

  • fludarabine phosphate.  // Royal Society of Medicine: Medicines;2002, p250 

    The article provides information on fludarabine phosphate, an antimetabolite cytotoxic drug which can be used as an anticancer treatment primarily of certain leukaemias. Administration is by injection.

  • The NF-κB pathway blockade by the IKK inhibitor PS1145 can overcome Imatinib resistance. Cilloni, D.; Messa, F.; Arruga, F.; Defilippi, I.; Morotti, A.; Messa, E.; Carturan, S.; Giugliano, E.; Pautasso, M.; Bracco, E.; Rosso, V.; Sen, A.; Martinelli, G.; Baccarani, M.; Saglio, G. // Leukemia (08876924);Jan2006, Vol. 20 Issue 1, p61 

    Imatinib represents at present the most attractive therapy for BCR-ABL positive leukemias, even though a percentage of CML patients develop resistance to this compound. For these resistant patients a therapeutic approach based on a combination of drugs is more likely to be effective. In the last...

  • Nilotinib better than imatinib, dasatinib for CML in Colombia.  // PharmacoEconomics & Outcomes News;1/21/2012, Issue 645, p4 

    The article reports on the claim of researchers that nilotinib is highly cost effective compared to imatinib and dominant over dasatinib in Colombia for patients with chronic myeloid leukaemia (CML). They found that nilotinib remained cost effective versus imatinib in over 85% of scenarios. In...

  • Fludara.  // Royal Society of Medicine: Medicines;2002, p250 

    The article provides information on Fludara, a proprietary, prescription-only preparation of the anticancer drug fludarabine phosphate. It can be used in the treatment of leukaemia, and is available in a form for injection.

  • Multiple Pathways of Apoptosis Induced by Roscovitine in Leukemic Cell Lines In Vitro. Hairong Song; Sidén, Åke; Hassan, Zuzana // Open Pharmacology Journal;2008, Vol. 2, p24 

    Roscovitine is a potent inhibitor of cyclin-dependent kinases (CDKs) that competes with the ATP binding pocket of kinases. Roscovitine has been shown to have cytotoxic effect on cancer cell lines in vitro and also in tumor xenografts in vivo. A strong synergistic effect in combination with...

  • Imatinib.  // Reactions Weekly;8/11/2007, Issue 1164, p15 

    The article describes the case of a 60-year-old woman who developed Stevens-Johnson syndrome (SJS) during treatment with imatinib for Philadelphia, Pennsylvania-positive chronic myeloid leukaemia (CML). The patient started treatment after being diagnosed with CML, and twelve days later, she...

  • Therapeutics: Pinch hitter. Novak, Kristine // Nature Reviews Cancer;Sep2004, Vol. 4 Issue 9, p662 

    Comments on Charles Sawyers and colleagues' study on the potential of a compound BMS-354825 to treat chronic myelogenous leukemia. Role of imatinib in inhibiting the kinase activity of BCR-ABL; Comparison between the effectiveness of imatinib and BMS-354825; Other classes of ABL inhibitors for...

  • Current Antimicrobial Usage for the Management of Infections in Leukemic Patients in Japan: Results of a Survey. Yoshida, Minoru; Ohno, Ryuzo // Clinical Infectious Diseases;7/1/2004 Supplement 1, Vol. 39, pS11 

    We report the findings of a questionnaire distributed by the Committee of Supportive Care of the Japan Adult Leukemia Study Group to 196 hospitals throughout Japan. For antimicrobial prophylaxis, the oral quinolones are prescribed by 38% of physicians and polymixin B by 31%. For antifungal...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics